Diagnoplex Secures 1.3M Swiss Francs

Diagnoplex SA, a Lausanne, Switzerland-based developer of molecular diagnostics for colon cancer, has secured 1.3m Swiss francs.

The round was led by Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group, with participation from Neomed and Initiative Capital Romandie.

Led by Stavros Therianos, Ph.D., Chief Executive Officer and founder, Diagnoplex develops Colox, a minimally-invasive blood test developed for the systematic screening and detection of early and advanced colorectal cancer.

The company intends to use the capital to obtain CE marking (European Conformity) for Colox.




Join the discussion